Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis
Authors' conclusion
CAB60, LEN, and apatinib are promising topical MKIs with statistically significant primary outcomes in RAIR-DTC patients, while CAB and anlotinib are effective in prolonging PFS in aMTC patients.
Study context
- Population
- Patients with refractory thyroid cancer: RAI-refractory DTC (radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC)) and advanced MTC (advanced medullary thyroid carcinoma (aMTC)); RCTs searched to December 2023
- Comparison
- Multikinase inhibitors (MKIs) vs other MKIs or placebo
- Outcome
- PFS and OS
Methodological detailsBayesian network meta-analysis, PRISMA, Cochrane risk of bias 2 tool
- Bayesian network meta-analysis
- PRISMA
- Cochrane risk of bias 2 tool
Pooled result
As reported in the abstract
- RAIR-DTC: highest prolonged progression-free survival (PFS) with CAB60, followed by LEN18 or LEN24, and apatinib
- aMTC: PFS also improved with CAB140, CAB60 or anlotinib
- RAIR-DTC: significantly greater overall survival (OS) improvement with CAB60, LEN24, anlotinib and sorafenib
- aMTC: no statistical differences in OS
Safety
Adverse events
- High-dose MKIs (CAB, LEN, vandetanib) increased incidence of AEs vs low-dose MKIs
Original publication
Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab. Published 6 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →